Business Wire - Total Worldwide Market for Antibiotics and Antifungals Was US$25 Billion in 2005, But Is Predicted To Fall To Between US$15 and US$20 Billion By 2016
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets. paroxetine. com/reports/c46926) has announced the addition of The Global Market for AntiMicrobials and Antifungals; Challenging Resistance to 2015 to their offering.
Antibiotic resistance is a significant problem which is negatively impacting prescribing patterns, consequently reducing antibiotic usage. The total worldwide market for antibiotics and antifungals was US$25 billion in 2005, but is predicted to fall to between US$15 and US$20 billion by 2016. This forecast is based on a number of factors, but largely due to declining rates of antibiotic prescriptions for respiratory infections - a major segment of the market. Other contributing factors include the loss of market exclusivity for a number of popular branded antibiotics, including Abbott’s Biaxin and Pfizer’s Zithromax in 2005. Generic competitors of these drugs have already been launched and are set to make serious inroads on the branded market in the years to come.
Related Results
Popular prescription drugs
PFIZER.(Brief Article)(Statistical Data Included)
The Boston Globe business briefs column.
Pfizer: growth amid adversity
Local Focus.(Business)
In this unique market analysis report from Spectra Intelligence, The Global Market for Antimicrobials and Antifungals: Challenging Resistance to 2016, the reader will be presented with a comprehensive asessment of the global market for anti-infectives and antifungals. Included in the analysis are therapeutics to combat the lethal microorganisms MRSA, C. difficile, and the highly infectious agents potentially used in bioterrorism. The report also provides current sales and prescription trends for antibiotics and antifungals and a detailed review of the current armamentarium of marketed antibiotics and antifungals. Resistance mechanisms and efforts to target those mechanisms in drug discovery are also discussed. Furthermore, mechanisms of action of current and novel anti-infective therapeutics, side effects, and how differences in dosage formulations can affect their attractiveness to physicians and patients are also detailed. The report also provides an up-to-date extensive list of companies engaged in antibacterial and antifungal drug discovery and lists some of the novel scientific approaches being taken, including chemical biology, toxicogenomics, and computational approaches. It further documents efforts by companies to extend profits on drugs that are off-patent by developing new formulations with additional advantages benefiting patient compliance. Pipeline products and their advantages and disadvantages are also covered in-depth in the market analysis.
Content Outline:
List of Tables
List of Figures
List of Abbreviations
Executive Summary
Objective of the Report
Research Methodology
Chapter 1. Introduction To Antibiotics And Antifungals
Chapter 2. Bacterial And Fungal Infections And Diseases
Chapter 3. Classic Antibiotics And Antifungals: Pipeline Insights
Chapter 4. New Structures And/Or Novel Targets: Approved Or In The Pipeline
Chapter 5. Theworldmarket for Anti-Infectives And Antifungals
Chapter 6. Challenges In Developing Andmarketing New Antibiotics
Chapter 7. Companies Marketing Or Developing Antimicrobials And Antifungals
Some Companies Mentioned:
Abbott Laboratories
Achaogen
Achillion
Activbiotics
Advanced Life Sciences
Advancis
Agilent
Alpharx
Arpida Ltd.
Astrazeneca
Bausch & Lomb
BAyer
Biovertis
Centocor
Ceragenix Pharmaceuticals
Cerexa
Chiron
Cubist Pharmaceuticals
Enanta Pharmaceuticals
Genelogic
GlaxoSmithKline
Roche
Inhibitex
Intercell
Johnson & Johnson
Ketec
Kyorin
Merck
Microcide
Morphochem
Nanostream
Novartis
Novexel
Novozymes
Oragenics
Pfizer
Polymedix
Replidyne
Sanofi-Aventis
Schering-Plough
Toyama Chemical
Vertex Pharmaceuticals
Vicuron
Wyeth
For more information visit http://www.researchandmarkets.com/reports/c46926
COPYRIGHT 2006 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning